FDA grants fast track status to AC Immune for ACI 7104 Parkinson’s immunotherapy

Swiss biotechnology company AC Immune announced that the United States Food and Drug Administration has granted fast track designation and cleared trial expansion for its experimental treatment ACI 7104. This decision allows the company to extend its ongoing Phase 2 VacSYn study into clinical trial sites across the United States. Designed for people with early stage Parkinson's, the treatment is an active immunotherapy that aims to prompt the human immune system to generate its own protective antibodies. The treatment targets alpha synuclein, a protein that misfolds and forms toxic clumps inside brain cells. These protein aggregates trigger inflammation and contribute to the gradual loss of nerve cells that characterises the condition. Rather than delivering synthetic antibodies from an outside source, ACI 7104 acts like a vaccine to train the body to recognise and clear these harmful protein clumps before they spread further. The regulatory update follows interim results from the first part of the VacSYn trial, which evaluated participants over 76 weeks. According to company reports, the treatment was well tolerated without significant safety concerns and generated an antibody response in all participants. Researchers also observed encouraging trends across biological markers and clinical measures. However, these initial findings remain preliminary. Full results from the 100 week landmark expected in the second half of 2026 will provide a clearer picture of whether these biological responses translate into meaningful slowing of condition progression. To assess long term effects, a four million dollar grant from the Vijay and Marie Goradia Charitable Foundation will fund an additional two years of participant monitoring in the first phase of the trial. While fast track status provides AC Immune with more frequent communication with regulators and potential pathways for expedited review, it is important to note that the designation does not guarantee eventual approval or confirm clinical success. Rigorous testing across larger groups of people with Parkinson's will ultimately decide whether ACI 7104 can deliver genuine, lasting benefits.